After review by the Data and Safety Monitoring Board, the dosing of OCU200 in patients with diabetic macular edema (DME) will continue.

Ocugen Inc. closed 73.92% short of its 52-week high of $2.11, which the company reached on March 25th.

Ocugen has received approval from the DSMB to begin dosing the second cohort of patients in a trial of OCU200 for diabetic ...

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced progress in its Phase 1 clinical trial for OCU200, a novel biologic ...

Ocugen Inc. closed 75.47% below its 52-week high of $2.11, which the company reached on March 25th.

Ocugen (OCGN) announced that the Data and Safety Monitoring Board for the OCU200 clinical trial recently convened and reviewed safety data ...

Full Year 2024 Results Key Financial Results Net loss: US$54.1m (loss narrowed by 14% from ...

Ocugen Inc (OCGN) outlines pivotal trial progress and financial strategies while navigating increased expenses and market ...

Throughout the last three months, 5 analysts have evaluated Ocugen OCGN, offering a diverse set of opinions from bullish to bearish. The table below offers a condensed view of their recent ratings ...

Tiffany Hamilton; Head of Communications; Ocugen Inc. Shankar Musunuri; Chairman of the Board, Chief Executive Officer & Co-founder; Ocugen Inc. Ramesh Ramachandran; ...

Ocugen, Inc. (OCGN) reported its Q4 2024 earnings, showing a narrower-than-expected net loss and outperforming revenue forecasts. The company’s EPS stood at -$0.05, surpassing the forecasted -$0.06.